Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-8: KTE-X19 in r/r CLL and SLL
NCT03624036Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of brexucabtagene autoleucel in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (5 arms), sponsored by Kite Pharma. Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities up to 58 days. Started Nov 2018; status: terminated.
02
Drugs
brexucabtagene autoleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03624036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624036.